Novo Nordisk confirmed in October last year that its Victoza 6mg/mL pre-filled injection pens have been discontinued. In a statement made to The Pharmaceutical Journal, Novo Nordisk said the ...

Novo Nordisk increased R&D investments from 13.6% in 2022 to 14.0% in 2023. The company also announced that it would be expanding its presence in the pen needles market through a research hub in ...

The company has introduced two new liraglutide injectable pens to the UK market ... Liraglutide, initially sold by Denmark’s Novo Nordisk (NOV: N) under the brand names Victoza and Saxenda, among ...

One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it ...

Ozempic (semaglutide) is prescribed to treat type 2 diabetes mellitus. It works by stimulating insulin to manage blood sugar levels. It also slows down digestion and provides signals to the brain that ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.

Wegovy is also available through NovoCare Pharmacy, which directly ship all dose strengths at a cost of $499 per month for ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...